|
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
No Relationships to Disclose |